ArticleAnnals of gastroenterological surgery2023
Long-term changes in bone mineral density in postoperative patients with esophageal cancer.
Article in Annals of gastroenterological surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 6 citations in OpenAlex.
- Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer.Annals of surgical oncology · 2026Article
- Risk Stratification of Postoperative Recurrence After Adjuvant Nivolumab for Resected Locally Advanced Esophageal Cancer: A Real-World Study.Annals of surgical oncology · 2026Article
- Learning curve for the abdominal procedure in total robot-assisted minimally invasive esophagectomy with simultaneous cervical approach: an initial experience.BMC surgery · 2026Article
- Long-Term Survival of Two Versus Three Courses of Preoperative Cisplatin and Fluorouracil Plus Docetaxel for Locally Advanced Esophageal Cancer: A Multicenter Randomized Phase II Trial.Annals of gastroenterological surgery · 2025Article
- Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Survival Impact of Adjuvant Nivolumab Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemotherapy with Docetaxel Plus 5-Fluorouracil and Cisplatin.Annals of surgical oncology · 2025Article
- A cross-cohort study identifies potential oral microbial markers for esophageal squamous cell carcinoma.iScience · 2024Article
- Long-term changes in bone mineral density in postoperative patients with esophageal cancer.Annals of gastroenterological surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of this study was to investigate long-term changes in bone mineral density (BMD) after esophagectomy, identify the risk factors for postoperative osteoporosis in patients with esophageal cancer and survival outcomes related to osteoporosis. Methods: We retrospectively evaluated BMD changes for 197 consecutive patients with thoracic esophageal cancer who were disease-free for 5 years after radical esophagectomy. Osteoporosis was diagnosed using computed tomography with an L1 attenuation threshold of ≤110 HU. Survival analysis was performed on 381 consecutive patients with 5-year follow-up after radical esophagectomy. Results: BMD decreased annually after esophagectomy. The median attenuation (HU) was 134.2 before surgery and 135.2, 127.4, 123.3, 115.2, 105.6, and 102.4 at 6 months and 1, 2, 3, 4, and 5 years after surgery, respectively. Osteoporosis was diagnosed in 25.9% patients before surgery and 23.3%, 29.4%, 40.1%, 46.7%, 54.8%, and 60.4% patients with osteoporosis were observed at 6 months and 1, 2, 3, 4, and 5 years after surgery, respectively. Postoperative BMD did not decrease in patients aged ≤54 years, those who had never been smokers, and those with no weight loss after esophagectomy. Multivariate analysis identified that age (≥65 years) at surgery and smoking history were independent risk factors for osteoporosis at 5 years after esophagectomy. Patients with preoperative osteoporosis tended to have worse prognosis in disease-free survival and overall survival than those without osteoporosis, who were more likely to die due to non-esophageal cancer. Conclusion: Esophageal cancer survivors are more likely to develop osteoporosis after esophagectomy, and preoperative osteoporosis might be associated with prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.